A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-06-26Actual
Enrollment · participants30Actual
Source updated2024-09-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.